Blagosklonny goes on to write that even though rapamycin may reverse some manifestations of aging, it is more effective at ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ ...

Palvella Therapeutics (PVLA) announced QTORIN rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations was ...

The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic ...

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

They analysed 18,400 articles, and 19 studies and showed that Rapamycin improved immune, cardiovascular, and skin health in ...

Kaupinen continued, “In addition to these two initial indications for QTORIN™ rapamycin ... rare genetic skin diseases with no FDA-approved therapies." ...

Matthew Korenberg was appointed as Chief Financial Officer in October 2024. Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior ...